Bishai W R, Rappuoli R, Murphy J R
Evans Department of Clinical Research, University Hospital, Boston, Massachusetts 02118.
J Bacteriol. 1987 Nov;169(11):5140-51. doi: 10.1128/jb.169.11.5140-5151.1987.
ABM508 is a recombinant fusion protein consisting of the N-terminal 485 amino acids of diphtheria toxin joined to alpha-melanocyte-stimulating hormone. When expressed in Escherichia coli under the control of the tox promoter and signal sequence, ABM508 is severely degraded. When overexpressed from a thermoinducible lambda pR promoter fusion, ABM508 is largely insoluble. We compared the expression of ABM508 (501 amino acids) to a full-length mutant form of the toxin (CRM197; 535 amino acids) and found that CRM197 showed minimal proteolysis. Thus, the removal of the C-terminal 50 amino acids of the toxin destabilizes the protein, making it a target for proteases. Proteolysis of ABM508 could be reduced by removal of the tox signal sequence (thereby directing the protein to the cytoplasm) and growth in lon and htpR mutant strains of E. coli. We also showed that the solubility of tox gene products expressed in E. coli was directly related to the growth temperature of the culture. Thus, a fragment A fusion protein (223 amino acids), ABM508, and CRM197 were found in soluble extracts when expressed at 30 degrees C but could not be released by the same procedures after growth at 42 degrees C. On the basis of these observations, we fused the coding sequences for mature ABM508 to the trc promoter (inducible at 30 degrees C by isopropyl-beta-D-thiogalactoside) and expressed this construct in a lon htpR strain of E. coli. This plasmid made 10 mg of soluble tox protein per liter of culture (7.7% of the total cell protein) or 14 times more than our previous maximal level. Extracts from lon htpR cells harboring this plasmid had high levels of ADP-ribosyltransferase activity, and although proteolysis still occurred, the major tox product corresponded to full-length ABM508.
ABM508是一种重组融合蛋白,由白喉毒素的N端485个氨基酸与α-黑素细胞刺激素连接而成。当在tox启动子和信号序列的控制下在大肠杆菌中表达时,ABM508会严重降解。当从热诱导型λ pR启动子融合体中过表达时,ABM508基本上不溶。我们将ABM508(501个氨基酸)的表达与毒素的全长突变形式(CRM197;535个氨基酸)进行了比较,发现CRM197的蛋白水解作用最小。因此,去除毒素的C端50个氨基酸会使蛋白质不稳定,使其成为蛋白酶的作用靶点。通过去除tox信号序列(从而将蛋白质导向细胞质)以及在大肠杆菌的lon和htpR突变株中生长,可以减少ABM508的蛋白水解作用。我们还表明,在大肠杆菌中表达的tox基因产物的溶解度与培养物的生长温度直接相关。因此,片段A融合蛋白(223个氨基酸)、ABM508和CRM197在30℃表达时可在可溶性提取物中发现,但在42℃生长后,相同的方法无法将它们释放出来。基于这些观察结果,我们将成熟ABM508的编码序列与trc启动子(可在30℃由异丙基-β-D-硫代半乳糖苷诱导)融合,并在大肠杆菌的lon htpR菌株中表达该构建体。该质粒每升培养物可产生10毫克可溶性tox蛋白(占总细胞蛋白的7.7%),是我们之前最高水平的14倍。携带该质粒的lon htpR细胞提取物具有高水平的ADP-核糖基转移酶活性,尽管蛋白水解作用仍然发生,但主要的tox产物对应于全长ABM508。